130 related articles for article (PubMed ID: 35320709)
21. SUMOylation modulates the transcriptional activity of androgen receptor in a target gene and pathway selective manner.
Sutinen P; Malinen M; Heikkinen S; Palvimo JJ
Nucleic Acids Res; 2014 Jul; 42(13):8310-9. PubMed ID: 24981513
[TBL] [Abstract][Full Text] [Related]
22. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer.
Sahu B; Laakso M; Ovaska K; Mirtti T; Lundin J; Rannikko A; Sankila A; Turunen JP; Lundin M; Konsti J; Vesterinen T; Nordling S; Kallioniemi O; Hautaniemi S; Jänne OA
EMBO J; 2011 Sep; 30(19):3962-76. PubMed ID: 21915096
[TBL] [Abstract][Full Text] [Related]
23. FOXP1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells.
Takayama K; Horie-Inoue K; Ikeda K; Urano T; Murakami K; Hayashizaki Y; Ouchi Y; Inoue S
Biochem Biophys Res Commun; 2008 Sep; 374(2):388-93. PubMed ID: 18640093
[TBL] [Abstract][Full Text] [Related]
24. Androgen Receptor Enhances p27 Degradation in Prostate Cancer Cells through Rapid and Selective TORC2 Activation.
Fang Z; Zhang T; Dizeyi N; Chen S; Wang H; Swanson KD; Cai C; Balk SP; Yuan X
J Biol Chem; 2012 Jan; 287(3):2090-8. PubMed ID: 22139837
[TBL] [Abstract][Full Text] [Related]
25. A competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes.
Cherian MT; Wilson EM; Shapiro DJ
J Biol Chem; 2012 Jul; 287(28):23368-80. PubMed ID: 22589544
[TBL] [Abstract][Full Text] [Related]
26. Formation of AR-SMRT binding in prostate cancer cells treated with natural histone deacetylase inhibitor.
Trtková K; Pašková L; Matiješčuková N; Kolář Z
Cancer Biomark; 2010; 7(2):79-90. PubMed ID: 21178266
[TBL] [Abstract][Full Text] [Related]
27. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.
Wang Q; Li W; Zhang Y; Yuan X; Xu K; Yu J; Chen Z; Beroukhim R; Wang H; Lupien M; Wu T; Regan MM; Meyer CA; Carroll JS; Manrai AK; Jänne OA; Balk SP; Mehra R; Han B; Chinnaiyan AM; Rubin MA; True L; Fiorentino M; Fiore C; Loda M; Kantoff PW; Liu XS; Brown M
Cell; 2009 Jul; 138(2):245-56. PubMed ID: 19632176
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of androgen receptor transactivation function by adenovirus type 12 E1A undermines prostate cancer cell survival.
Li D; Tian G; Wang J; Zhao LY; Co O; Underill ZC; Mymryk JS; Claessens F; Dehm SM; Daaka Y; Liao D
Prostate; 2018 Nov; 78(15):1140-1156. PubMed ID: 30009471
[TBL] [Abstract][Full Text] [Related]
29. p68/DdX5 supports β-catenin & RNAP II during androgen receptor mediated transcription in prostate cancer.
Clark EL; Hadjimichael C; Temperley R; Barnard A; Fuller-Pace FV; Robson CN
PLoS One; 2013; 8(1):e54150. PubMed ID: 23349811
[TBL] [Abstract][Full Text] [Related]
30. Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions.
Decker KF; Zheng D; He Y; Bowman T; Edwards JR; Jia L
Nucleic Acids Res; 2012 Nov; 40(21):10765-79. PubMed ID: 23019221
[TBL] [Abstract][Full Text] [Related]
31. Androgen receptor-mTOR crosstalk is regulated by testosterone availability: implication for prostate cancer cell survival.
Wu Y; Chhipa RR; Cheng J; Zhang H; Mohler JL; Ip C
Anticancer Res; 2010 Oct; 30(10):3895-901. PubMed ID: 21036700
[TBL] [Abstract][Full Text] [Related]
32. Hierarchical Phosphorylation of HOXB13 by mTOR Dictates Its Activity and Oncogenic Function in Prostate Cancer.
Chen Y; Dufour CR; Han L; Li T; Xia H; Giguère V
Mol Cancer Res; 2023 Oct; 21(10):1050-1063. PubMed ID: 37409967
[TBL] [Abstract][Full Text] [Related]
33. Progesterone Receptor Expression in the Benign Prostatic Hyperplasia and Prostate Cancer Tissues, Relation with Transcription, Growth Factors, Hormone Reception and Components of the AKT/mTOR Signaling Pathway.
Spirina LV; Kovaleva IV; Usynin EA; Goorbunov AK; Kondakova IV
Asian Pac J Cancer Prev; 2020 Feb; 21(2):423-429. PubMed ID: 32102520
[TBL] [Abstract][Full Text] [Related]
34. Genome-wide analysis of androgen receptor targets reveals COUP-TF1 as a novel player in human prostate cancer.
Perets R; Kaplan T; Stein I; Hidas G; Tayeb S; Avraham E; Ben-Neriah Y; Simon I; Pikarsky E
PLoS One; 2012; 7(10):e46467. PubMed ID: 23056316
[TBL] [Abstract][Full Text] [Related]
35. Modeling truncated AR expression in a natural androgen responsive environment and identification of RHOB as a direct transcriptional target.
Tsai HC; Boucher DL; Martinez A; Tepper CG; Kung HJ
PLoS One; 2012; 7(11):e49887. PubMed ID: 23209612
[TBL] [Abstract][Full Text] [Related]
36. Integrative functional genomics identifies an enhancer looping to the SOX9 gene disrupted by the 17q24.3 prostate cancer risk locus.
Zhang X; Cowper-Sal lari R; Bailey SD; Moore JH; Lupien M
Genome Res; 2012 Aug; 22(8):1437-46. PubMed ID: 22665440
[TBL] [Abstract][Full Text] [Related]
37. The role of sLZIP in cyclin D3-mediated negative regulation of androgen receptor transactivation and its involvement in prostate cancer.
Kim Y; Kim J; Jang SW; Ko J
Oncogene; 2015 Jan; 34(2):226-36. PubMed ID: 24441043
[TBL] [Abstract][Full Text] [Related]
38. Androgen receptor enhancer usage and the chromatin regulatory landscape in human prostate cancers.
Stelloo S; Bergman AM; Zwart W
Endocr Relat Cancer; 2019 May; 26(5):R267-R285. PubMed ID: 30865928
[TBL] [Abstract][Full Text] [Related]
39. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.
Kaarbø M; Mikkelsen OL; Malerød L; Qu S; Lobert VH; Akgul G; Halvorsen T; Maelandsmo GM; Saatcioglu F
Cell Oncol; 2010; 32(1-2):11-27. PubMed ID: 20203370
[TBL] [Abstract][Full Text] [Related]
40. Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer.
Wu D; Sunkel B; Chen Z; Liu X; Ye Z; Li Q; Grenade C; Ke J; Zhang C; Chen H; Nephew KP; Huang TH; Liu Z; Jin VX; Wang Q
Nucleic Acids Res; 2014 Apr; 42(6):3607-22. PubMed ID: 24423874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
